PRE Prenetics Global Ltd IFRS Annual reports only
Pharmaceutical Preparations · Nasdaq · SEC CIK 1876431 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20242024-12-31 | FY20232023-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $30.62M | $21.74M |
| Cost of revenue | $15.22M | $12.91M |
| Gross profit | $15.40M | $8.83M |
| R&D expense | $10.92M | $11.66M |
| Operating income | -$48.14M | -$51.91M |
| Pretax income | -$57.70M | -$56.67M |
| Income tax | -$7.87M | -$269,000 |
| Net income | -$46.30M | -$62.72M |
| EPS (basic) | -3.71 | -5.58 |
| EPS (diluted) | -3.71 | -5.58 |
| Weighted avg. shares (diluted) | 12.49M | 11.25M |
| Balance sheet | ||
| Cash & equivalents | $52.25M | $45.71M |
| Short-term investments | $0 | $16.00M |
| Receivables | $16.77M | $17.66M |
| Inventory | $6.57M | $3.13M |
| Current assets | $86.15M | $93.66M |
| PP&E, netmay include right-of-use assets (IFRS) | $7.81M | $5.78M |
| Goodwill | $37.36M | $29.17M |
| Intangibles | $11.57M | $13.43M |
| Total assets | $213.57M | $254.17M |
| Current liabilities | $36.55M | $39.48M |
| Total liabilities | $42.23M | $44.01M |
| Shareholders' equity | $170.39M | $206.36M |
| Shares outstanding | 12.98M | 12.21M |
| Cash flow statement | ||
| Operating cash flow | -$28.87M | -$13.77M |
| Capital expenditure | $1.01M | $345,000 |
| Free cash flow | -$29.88M | -$14.11M |
| Investing cash flow | $38.54M | -$82.95M |
| Financing cash flow | -$3.34M | -$4.70M |
| Stock-based compensation | $7.85M | $10.59M |
Free plan shows the latest 2 periods; Pro shows all 5 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.